JP5855670B2 - 精神疾患の治療方法 - Google Patents
精神疾患の治療方法 Download PDFInfo
- Publication number
- JP5855670B2 JP5855670B2 JP2013537287A JP2013537287A JP5855670B2 JP 5855670 B2 JP5855670 B2 JP 5855670B2 JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013537287 A JP2013537287 A JP 2013537287A JP 5855670 B2 JP5855670 B2 JP 5855670B2
- Authority
- JP
- Japan
- Prior art keywords
- adhd
- lurasidone
- pharmaceutically acceptable
- treatment
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000020016 psychiatric disease Diseases 0.000 title description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 102
- 150000003839 salts Chemical class 0.000 claims description 51
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 49
- 229960001432 lurasidone Drugs 0.000 claims description 48
- 239000002253 acid Substances 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 41
- 230000006872 improvement Effects 0.000 claims description 35
- 239000000018 receptor agonist Substances 0.000 claims description 29
- 229940044601 receptor agonist Drugs 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 208000013403 hyperactivity Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- FRPJGTNLZNXQEX-UHFFFAOYSA-N 2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 FRPJGTNLZNXQEX-UHFFFAOYSA-N 0.000 claims description 6
- DNULYRGWTFLJQL-UHFFFAOYSA-N N-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C(=CC=CC=2)C#N)=C1 DNULYRGWTFLJQL-UHFFFAOYSA-N 0.000 claims description 6
- PUMMPCXNEPHBNN-UHFFFAOYSA-N abt-670 Chemical compound CC1=CC=CC(C(=O)NCN2CCC(CC2)C=2[N+](=CC=CC=2)[O-])=C1 PUMMPCXNEPHBNN-UHFFFAOYSA-N 0.000 claims description 6
- RAIDOKRWKAIHOH-UHFFFAOYSA-N n-[[3-(cyclopenten-1-yl)phenyl]methyl]-2-[(2,2-dimethyl-3h-1-benzofuran-7-yl)oxy]ethanamine Chemical compound C=12OC(C)(C)CC2=CC=CC=1OCCNCC(C=1)=CC=CC=1C1=CCCC1 RAIDOKRWKAIHOH-UHFFFAOYSA-N 0.000 claims description 6
- -1 PIP-3EA Chemical compound 0.000 claims description 5
- STIRDGXSGQTCAJ-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine-7-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC2=C3C=CC=C(N3N=C2)C#N)CC1 STIRDGXSGQTCAJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 3
- BJWYIHWMKMZYRS-IBGZPJMESA-N (6s)-2-phenyl-6-[(4-phenylpiperazin-1-yl)methyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C([C@H](N1)CN2CCN(CC2)C=2C=CC=CC=2)CN=C1C1=CC=CC=C1 BJWYIHWMKMZYRS-IBGZPJMESA-N 0.000 claims description 2
- QRYAMGGRUIKACE-SFHVURJKSA-N 1-phenyl-4-[[(5r)-2-phenyl-4,5-dihydro-1h-imidazol-5-yl]methyl]piperazine Chemical compound C([C@H](N1)CN2CCN(CC2)C=2C=CC=CC=2)N=C1C1=CC=CC=C1 QRYAMGGRUIKACE-SFHVURJKSA-N 0.000 claims description 2
- TWVIJESEEXGVPP-UHFFFAOYSA-N 2-[(4-phenylpiperazin-1-yl)methyl]-1h-indole-5-carbonitrile Chemical compound C=1C2=CC(C#N)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=C1 TWVIJESEEXGVPP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 92
- 238000012360 testing method Methods 0.000 description 55
- 230000006870 function Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 26
- 229960002863 lurasidone hydrochloride Drugs 0.000 description 23
- NEKCRUIRPWNMLK-SCIYSFAVSA-N lurasidone hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 NEKCRUIRPWNMLK-SCIYSFAVSA-N 0.000 description 23
- 241001515942 marmosets Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000011630 spontaneously hypertensive stroke prone rat Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011706 wistar kyoto rat Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229960005017 olanzapine Drugs 0.000 description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010020400 Hostility Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 241000288950 Callithrix jacchus Species 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229960002828 atomoxetine hydrochloride Drugs 0.000 description 1
- LUCXVPAZUDVVBT-UNTBIKODSA-N atomoxetine hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C LUCXVPAZUDVVBT-UNTBIKODSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013537287A JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41108110P | 2010-11-08 | 2010-11-08 | |
| US61/411,081 | 2010-11-08 | ||
| JP2011033453 | 2011-02-18 | ||
| JP2011033453 | 2011-02-18 | ||
| PCT/JP2011/062314 WO2012063513A1 (en) | 2010-11-08 | 2011-05-24 | Method of treatment for mental disorders |
| JP2013537287A JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240067A Division JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541582A JP2013541582A (ja) | 2013-11-14 |
| JP2013541582A5 JP2013541582A5 (enExample) | 2014-07-10 |
| JP5855670B2 true JP5855670B2 (ja) | 2016-02-09 |
Family
ID=46020227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537287A Active JP5855670B2 (ja) | 2010-11-08 | 2011-05-24 | 精神疾患の治療方法 |
| JP2015240067A Active JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240067A Active JP6470164B2 (ja) | 2010-11-08 | 2015-12-09 | 精神疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8258139B2 (enExample) |
| EP (1) | EP2638038A4 (enExample) |
| JP (2) | JP5855670B2 (enExample) |
| CN (1) | CN103180315A (enExample) |
| CA (1) | CA2814828C (enExample) |
| WO (1) | WO2012063513A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565776A (zh) * | 2012-07-25 | 2014-02-12 | 天津市汉康医药生物技术有限公司 | 一种稳定的鲁拉西酮胶囊药物组合物 |
| WO2014192868A1 (ja) * | 2013-05-30 | 2014-12-04 | 大日本住友製薬株式会社 | 環状アミノメチルピリミジン誘導体 |
| US10272080B2 (en) | 2013-09-13 | 2019-04-30 | Florida State University Research Foundation, Inc. | Selective dopamine D4 receptor agonists for treatment of working memory deficits |
| JP6594351B2 (ja) | 2014-06-16 | 2019-10-23 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| DK36291D0 (da) | 1991-03-01 | 1991-03-01 | Lundbeck & Co As H | Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser |
| GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| IL110011A (en) | 1994-06-13 | 2004-09-27 | Yeda Res & Dev | Pharmacological preparations for the treatment of schizophrenia |
| WO1996014297A1 (en) | 1994-11-04 | 1996-05-17 | Sumitomo Pharmaceuticals Company, Limited | Novel lactam derivatives |
| JP3775823B2 (ja) | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
| US5688798A (en) | 1995-10-10 | 1997-11-18 | Hoffmann-La Roche Inc. | Pyrimidine compounds |
| PT1073432E (pt) | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
| JP2000281576A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | イミド誘導体を含有するプロテオグリカン生成促進剤 |
| AR027134A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
| JP2004518628A (ja) | 2000-09-14 | 2004-06-24 | グリアテック インコーポレイテッド | 窒素含有化合物およびそれらのグリシン輸送阻害薬としての使用法 |
| EP1327440B1 (en) | 2000-09-22 | 2009-05-13 | Dainippon Sumitomo Pharma Co., Ltd. | Oral preparations with favorable disintegration characteristics |
| MXPA03006003A (es) | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| US7067507B2 (en) | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| JP4568463B2 (ja) | 2001-11-05 | 2010-10-27 | 独立行政法人科学技術振興機構 | ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物 |
| JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
| JP2006505489A (ja) | 2002-02-08 | 2006-02-16 | アボット・ラボラトリーズ | 精神分裂病の治療のための併用療法 |
| ATE431147T1 (de) | 2002-08-22 | 2009-05-15 | Dainippon Sumitomo Pharma Co | Mittel zur behandlung des integrationsdysfunktionssyndroms |
| CA2531980C (en) | 2003-06-23 | 2013-09-17 | Dainippon Sumitomo Pharma Co., Ltd. | Imide derivatives as therapeutic agents for senile dementia |
| EP1726952A4 (en) | 2004-02-20 | 2008-06-18 | Dainippon Sumitomo Pharma Co | METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA |
| US7122683B2 (en) * | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| ES2390353T3 (es) * | 2005-06-13 | 2012-11-12 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación de disolución |
| TW200812993A (en) | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| US7662820B2 (en) | 2006-10-30 | 2010-02-16 | Sanrx Pharmaceuticals, Inc. | Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon |
| AU2008236705B2 (en) * | 2007-04-04 | 2014-01-23 | Merck Sharp & Dohme Corp. | Therapeutic agents |
| JP2008135074A (ja) | 2008-02-25 | 2008-06-12 | Fujitsu Ltd | 情報公開方法および情報公開装置 |
-
2011
- 2011-05-23 US US13/113,703 patent/US8258139B2/en active Active
- 2011-05-24 WO PCT/JP2011/062314 patent/WO2012063513A1/en not_active Ceased
- 2011-05-24 EP EP11840252.8A patent/EP2638038A4/en not_active Withdrawn
- 2011-05-24 JP JP2013537287A patent/JP5855670B2/ja active Active
- 2011-05-24 CN CN2011800528248A patent/CN103180315A/zh active Pending
- 2011-05-24 CA CA2814828A patent/CA2814828C/en active Active
-
2012
- 2012-07-20 US US13/555,044 patent/US9259423B2/en active Active
-
2015
- 2015-12-09 JP JP2015240067A patent/JP6470164B2/ja active Active
-
2016
- 2016-01-13 US US14/994,939 patent/US9827242B2/en active Active
- 2016-01-13 US US14/995,044 patent/US10098875B2/en active Active
-
2018
- 2018-09-24 US US16/139,647 patent/US20190022091A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10098875B2 (en) | 2018-10-16 |
| CN103180315A (zh) | 2013-06-26 |
| US20120115879A1 (en) | 2012-05-10 |
| US20190022091A1 (en) | 2019-01-24 |
| US20130018056A1 (en) | 2013-01-17 |
| JP2016094440A (ja) | 2016-05-26 |
| US9827242B2 (en) | 2017-11-28 |
| US8258139B2 (en) | 2012-09-04 |
| US20160129000A1 (en) | 2016-05-12 |
| JP2013541582A (ja) | 2013-11-14 |
| WO2012063513A1 (en) | 2012-05-18 |
| EP2638038A4 (en) | 2014-03-12 |
| CA2814828C (en) | 2019-09-10 |
| US20160193205A1 (en) | 2016-07-07 |
| US9259423B2 (en) | 2016-02-16 |
| CA2814828A1 (en) | 2012-05-18 |
| EP2638038A1 (en) | 2013-09-18 |
| JP6470164B2 (ja) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510314A (ja) | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 | |
| US10980802B2 (en) | Medicament for treating mental and behavioural disorders | |
| JP6611896B2 (ja) | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト | |
| JP6470164B2 (ja) | 精神疾患の治療方法 | |
| KR20160048930A (ko) | 알츠하이머 질환의 치료에 사용하기 위해 콜린에스테라제 저해제와 조합된 h3 수용체 길항제 | |
| Torigoe et al. | Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| US20220387396A1 (en) | Methods of treating the symptoms of autism spectrum disorder | |
| US11957671B2 (en) | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases | |
| CN112822997A (zh) | 用于治疗孤独症的组合物和方法 | |
| RU2635522C2 (ru) | Способы поддержания, лечения или улучшения когнитивной функции | |
| JP2019516758A (ja) | 不安障害を治療するための（２Ｓ）−１−［４−（３，４−ジクロロフェニル）ピペリジン−１−イル］−３−［２−（５−メチル−１，３，４−オキサジアゾール−２−イル）ベンゾ［ｂ］フラン−４−イルオキシ］プロパン−２−オールまたはその代謝産物 | |
| JP2013023459A (ja) | 精神疾患治療剤 | |
| CN106163514B (zh) | 注意缺陷和多动性障碍的预防及治疗剂 | |
| TW201642847A (zh) | 用於靜脈內投與反丁烯二酸酯以治療神經疾病之方法及組合物 | |
| FR2976179A1 (fr) | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150615 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5855670 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |